このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sera Prognostics 過去の業績

過去基準チェック /06

Sera Prognosticsの収益は年間平均-17.6%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 54.8%割合で増加しています。

主要情報

-17.6%

収益成長率

73.4%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	54.8%
株主資本利益率	-52.2%
ネット・マージン	-16,395.1%
前回の決算情報	31 Mar 2024

Recent updates

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

Mar 24

Sera Prognostics: The Pregnancy Company On A Hot Streak

Jan 10

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Oct 03

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Jun 15

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Feb 16

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15

収支内訳

Sera Prognostics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:SERA 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-34	23	15
31 Dec 23	-36	25	15
30 Sep 23	-38	26	15
30 Jun 23	-42	29	15
31 Mar 23	-43	30	15
31 Dec 22	-44	31	14
30 Sep 22	-47	34	14
30 Jun 22	-46	34	12
31 Mar 22	-41	30	12
31 Dec 21	-35	24	11
30 Sep 21	-28	18	10
30 Jun 21	-23	14	9
31 Mar 21	-22	12	8
31 Dec 20	-20	10	8
31 Dec 19	-17	7	9

質の高い収益: SERAは現在利益が出ていません。

利益率の向上: SERAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SERAは利益が出ておらず、過去 5 年間で損失は年間17.6%の割合で増加しています。

成長の加速: SERAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SERAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: SERAは現在利益が出ていないため、自己資本利益率 ( -52.16% ) はマイナスです。

Sera Prognostics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Recent updates

Chief Data Officer recently sold US$86k worth of stock

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President recently sold US$225k worth of stock

Sera Prognostics: The Pregnancy Company On A Hot Streak

Independent Chairman notifies of intention to sell stock

General Counsel recently sold US$52k worth of stock

New major risk - Share price stability

Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success

Consensus revenue estimates decrease by 14%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 55%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Sera Prognostics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Market cap size

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023

Sera Prognostics, Inc. Announces Board Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues miss analyst expectations

Sera Prognostics, Inc. Announces Positive Top-Line Data from AVERT PRETERM TRIAL

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Sera Prognostics, Inc. Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the Pretrm® Test-And-Treat Strategy Across Diverse Populations

Insufficient new directors

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Sera Prognostics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$7.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Chief Scientific Officer notifies of intention to sell stock

Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee

Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell 2500 Value Index

Sera Prognostics, Inc. Announces Publication of Data Demonstrating Improved Performance of its PreTRM Test with More Precise Gestational Age

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sera Prognostics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Sera Prognostics, Inc., Annual General Meeting, Jun 03, 2022

Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Scientific Officer exercised options to buy US$282k worth of stock.

Insufficient new directors

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Sera Prognostics Inc. Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth

Third quarter 2021 earnings released: US$0.39 loss per share

Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06